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Background: Antipsychotic medications are the first-line treatment for schizophrenia. 
Medication non-adherence is often a problem among patients with schizophrenia, leading 
to relapse, rehospitalization, and high cost-burden. First-generation antipsychotics were 
first developed to treat schizophrenia; however, the higher risk of extra-pyramidal side 
effects have made them unfavorable in comparison to second-generation antipsychotics 
(SGA). Nevertheless, antipsychotic adherence is often suboptimal, which can lead to 
relapse and rehospitalization. Long-acting injectable (LAI) antipsychotics were 
developed to help improve adherence, thereby reducing rates of relapse. However, this 
drug class is associated with high treatment cost while the more common oral 
antipsychotics are inexpensive in comparison. 
Methods: Data from Optum’s de-identified Clinformatics Data Mart Database from 
years 2010-2015, was utilized to conduct a retrospective cohort study and cost-
effectiveness analysis comparing the outcomes and cost of LAI second-generation 
antipsychotics (SGAs) with oral SGAs for the treatment of schizophrenia. Patients with a 
history of at least two inpatient hospitalizations for schizophrenia two years prior to a 
recent relapse hospitalization (index date) during 2012-2014 were identified. Patients 
were required to have a claim for a LAI SGA or oral SGA within 40 days of discharge 
from the index hospitalization. Patients were entered into a 12-month follow-up period 
during which medication cost, adherence, and medication switch or rehospitalization due 
to relapse were measured. A patient level descriptive analysis was conducted followed by 
developing a decision model for which an incremental cost-effectiveness ratio (ICER) 
was estimated comparing incremental cost of treatments and incremental effectiveness.
 
Results: 158 patients met the study’s inclusion-exclusion criteria. Of 158 patients, 135 
(85.4%) had a claim for an oral SGA within 40 days of index discharge and 23 (14.6%) 
had a claim for a LAI SGA. The mean age of the population was 48-years (standard 
deviation, SD +12.0) with similar distribution observed in gender (49.4% female). 
Patients experienced about 4 hospitalizations (SD +2.7) on average, prior to their index 
date and also had a mean index length of stay of about 10 days (SD +8.8). Compared to 
patients receiving oral SGAs, patients receiving LAIs experienced numerically higher 
adherence rates, numerically higher proportion of stable patients, and higher mean cost of 
medication ($1,339.20 vs. $282.90, p<.0001). A sensitivity analysis determined that 
change in the proportion of adherent patients prescribed LAIs had a large impact on the 
ICER value. 
Conclusion: Although statistically not significant, the LAI cohort was associated with 
numerically lower rates of switch or rehospitalization and a higher proportion of adherent 
patients compared to oral SGAs. While LAIs are associated with a much higher average 
monthly cost than their oral comparators, the decision analysis indicated that the 
additional expenditure was associated with improvement in the measured outcome. 
Further research is warranted examining populations with higher prevalence of 
schizophrenia to provide larger sample sizes and to measure cost-benefit, which may 
illustrate cost-avoidance through the cost of rehospitalization due to relapse.
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Schizophrenia is a lifelong, incurable, mental disorder that affects about 1% of the 
United States’ population.1 Schizophrenia typically develops in late adolescence to young 
adulthood and tends to occur earlier in males than in females.1 Patients with 
schizophrenia may experience “positive” symptoms including delusions, hallucinations 
and cognitive dysfunction as well as “negative” symptoms such as reduced expression 
and motivation.1 Such symptoms often put patients out of touch with reality and lower 
their mental awareness. Many patients turn to substance abuse as means to cope and self-
medicate. Patients with schizophrenia have about five times higher rate of tobacco 
smoking than that found in the general population2 and have higher prevalence of illicit 
drug use.3 Patients also live with a 5% suicide risk1 and are twelve times as likely to die 
from suicide compared with the general world population.4 Because of these factors and 
disease exacerbations, schizophrenia is associated with an increased mortality rate5 and a 
decrease in life expectancy of about 14.5 years compared to the average world 
population.6 
Antipsychotic medications are used as first-line treatment for schizophrenia in 
order to manage and control disease symptoms. There are first-generation (typical) and 
second-generation (atypical) antipsychotics. First-generation antipsychotics (FGAs), such 
as haloperidol or fluphenazine, are directly associated with extrapyramidal side effects 
such as tardive dyskinesia, drug induced parkinsonism and dystonias.7-9 Second-
generation antipsychotics (SGAs) have a decreased risk of extrapyramidal side effects 
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and hence may be preferred by patients. SGAs are also prescribed more frequently than 
first-generation antipsychotics.10 
Schizophrenia is a mental illness frequently seen in hospitals across the country. 
In 2010, schizophrenia was the second most hospitalized mental illness11 and in 2014, the 
second most common hospital visit among any inpatient stay occurring in 18-44 years 
age group (excluding maternal or neonatal principal diagnoses).12 Due to frequent 
hospitalizations, schizophrenia can cause substantial burden to the US healthcare 
system.13,14 Due to the severity of the disease, relapses are common in patients with 
schizophrenia. Patients who relapse are associated with high hospitalization rates and 
cost15 and patients with a history of relapse are associated with an even higher cost 
burden than those who do not experience relapses.16 
Relapse rates are often influenced by medication adherence,17 with low 
medication adherence being the leading cause of relapse in psychosis.18 Despite the direct 
correlation between relapse and non-adherence, adherence rates among patients with 
schizophrenia are often suboptimal.19-21 In order to address the difficulties in adhering to 
oral therapies and provide better outcomes, long-acting injectable antipsychotics (LAIs) 
were developed as an intra-muscular depot injection given by a clinician or pharmacist. 
Each dose can provide two-weeks to one-months’ worth of medication or more, 
potentially substituting 30 or more pills with one injection. LAIs are intended increase 
adherence and therefore decrease the potential of relapse and hospitalization. The first 
LAI SGA was approved in 2003, and these formulations increasingly began to become 
recognized for their usefulness in chronic patients.22 With additional LAIs being 
developed throughout the years, LAIs demonstrated their effectiveness in reducing 
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relapse rates and increasing patient adherence.23-26 However, the high cost of newer LAIs 
may prevent patients from receiving this beneficial treatment.27 
Several cost-effectiveness studies have been conducted comparing LAIs to oral 
antipsychotics. One non-US study conducted in Portugal compared the costs and 
effectiveness of oral olanzapine to LAI risperidone, paliperidone, and haloperidol.25 A 
decision model with adherence rates were utilized with a one-year timeframe. Outcomes 
of inpatient hospitalization due to relapse, emergency room admission, and stability were 
assessed. The authors reported that patients utilizing LAI paliperidone had a lower rate of 
relapse or emergency room admission and a higher cost than oral olanzapine. Although 
comprehensive, their study poses limitations that can be improved upon. As such this was 
a non-US study, therefore findings cannot be applied to the US population and US 
payers. The authors state that the model inputs used were based on various pieces of 
literature and clinical trials, this in return may limit its real-world applicability as data is 
not taken from a population sample or database. 
A Medicaid-based study analyzed the cost-effectiveness of paliperidone LAI to 
oral antipsychotics.28 The model utilized a decision model and was used to inform 
outcomes in stable patients over a 12-month period. The authors found that paliperidone 
LAI was associated with higher adherence and was projected to decrease psychiatric 
hospitalizations compared to oral antipsychotics. The authors state that paliperidone LAI 
substantially decreases costs over an 18-month period. However, the cost of medication 
was not incorporated into the model, instead the findings are reported with the potential 
cost prevented by implementing LAIs in comparison to oral antipsychotics. Data from 
this study was also obtained from three separate clinical trials, which may not represent a 
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real-world sample as patients are subject to strict inclusion and exclusion criteria and are 
often observed for a limited period of time. Two of the trials were also conducted 
globally and were subject to very different designs, according to the authors. 
Another cost-effectiveness study that compared LAIs to an oral antipsychotic was 
a decision model comparing LAI olanzapine to LAI risperidone, LAI paliperidone, LAI 
haloperidol, and oral olanzapine.26 The model was developed with a one-year time 
horizon, analyzing adherence rates and probability of relapse. LAI olanzapine was 
associated with lower inpatient and outpatient relapses and higher proportion of stable 
patients. LAI olanzapine had lower cost and better outcomes when compared to the other 
LAIs measured, however, oral olanzapine was associated with poorer outcomes but a 
lower cost. Similar to the Portugal study, the authors utilized literature and expert opinion 
to determine model inputs. The study also measured medication adherence as an initial 
characteristic of patients starting therapy, not accounting for possible changes in 
adherence throughout the model.  
Our study sought to improve upon the limitations of previous cost-effectiveness 
studies by analyzing LAIs and oral antipsychotics using claims data from a large 
commercial insurer in the US. Patients with schizophrenia are representative of a real-
world sample and model inputs are directly derived from an administrative claims 
database, limiting the potential of bias associated with obtaining model inputs from 
within the literature, as inputs are often derived from multiple sources and different study 
samples. Utilizing a retrospective database also allows for continuous measurement of 
recurring variables, such as adherence, within a defined follow-up period. This study is 
also not industry funded, which excludes the potential of conflict of interest. 
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The objective of this study was to evaluate the cost-effectiveness of LAI 
antipsychotics, specifically atypical antipsychotics, as an alternative to oral SGAs in the 
prevention of rehospitalization due to relapse or medication switch, for the treatment of 






















Study Design & Data Source 
A pharmacoeconomic analysis was conducted using data from a retrospective 
claims US-based database, in order to describe the utilization and cost-effectiveness of 
oral and LAI second-generation antipsychotic medications among patients with 
schizophrenia. 
Optum commercial claims database was utilized to complete this study. Optum’s de-
identified Clinformatics Data Mart Database29 is an administrative healthcare claims 
database for members of a national managed care commercial health insurer. Optum 
includes pharmacy claims, medical claims, lab results, standard pricing, member 
demographic, and inpatient confinement data. Inpatient claims are coded utilizing 
International Classification of Disease, 9th and 10th Revision, Clinical Modification (ICD-
9-CM, ICD-10-CM). Medical claims are coded with ICD-9, ICD-10, and Healthcare 
Common Procedure Coding System (HCPCS) codes. Pharmacy claims use the National 
Drug Code (NDC) coding system for prescription drug claims. All records and claims 
within the database are de-identified. This study utilized data from years 2010-2015. 
Study Population 
The study population consisted of patients with an inpatient claim of a primary 
diagnosis of schizophrenia (ICD-9 295*) identified during the years 1/1/2012-
11/21/2014. The most recent hospitalization during the timeframe was labeled as a 
patient’s “index hospitalization.” In addition, patients were also required to be 
continuously enrolled for at least two years before and one year and 40 days after the 
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index date. The exposure period was defined as any patient prescribed a LAI SGA or oral 
SGA within 40-days after discharge from their index hospitalization within the index 
period of 1/1/2012-11/21/2014. Patients not within the age range of 18 to 64-years on 
their index date were excluded from this study as well as patients with a LAI SGA claim 
prior to their index date. Patients with extensive inpatient care, defined as over 60-day 
length of stay, as their index hospitalization were excluded as the service provided to 
these outlier patients would likely be relatively distinct from the rest of the population.30 
Figure 1 depicts the patient flow chart with the inclusion and exclusion criteria, while 
Figure 2 depicts the study schematic diagram. Patients prescribed a LAI or oral dosage 
form of the LAI SGAs listed in Supplemental Table 1 were included in the study.  
Patients were categorized into two cohorts, oral SGA or LAI SGA based upon 
their drug claim during the exposure period. 
Study Measures 
The endpoints in this analysis were rehospitalization due to relapse, switching 
from exposure medication without rehospitalization due to relapse, or completion of the 
405-day follow-up period without switch or rehospitalization. Rehospitalization due to 
relapse was defined by any hospitalization within 405 days from a patient’s index date 
with a primary diagnosis of schizophrenia (ICD-9 295* or ICD-10 F20*, F25*). The 
follow-up for these patients ended on their date of rehospitalization. Switching 
medications was considered to be lack of effectiveness or tolerability provided by the 
exposure drug. This was defined as a patient discontinuing their exposure medication for 
at least 60 days after the remainder of available supply from the last exposure drug fill 
date.31,32 The follow-up for patients who switched medications concluded on the first 
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claim of any non-exposure antipsychotic after exhausting the remaining supply of their 
exposure antipsychotic. Patients with a 60-day gap but failing to have a claim for a non-
exposure antipsychotic before the end of follow-up were not considered to switch, the 
days without an antipsychotic medication contributed to the patient’s adherence rate. 
Upon rehospitalization, switch, or completion of follow-up, adherence rates were 
calculated. Adherence rates were calculated using medication possession ratios (MPR) 
and is only representative of adherence to the exposure drug. MPR was calculated as the 
ratio of the total number of nonoverlapped days covered by antipsychotics during the 
follow-up period, over the total days until relapse from index hospitalization, switch, or 
end of follow-up (405 days).33 Rehospitalization due to relapse was the primary outcome 
assessed in this study and was measured prior to switching medications. However, if a 
patient were to switch treatments before relapse, their adherence rates were calculated 
until switch. Adherence was categorized using MPR thresholds of ≥0.8 and <0.8. 
Acceptable adherence has been defined by others as an MPR ratio of 0.8 or above, with 
poor adherence below 0.8.18, 19 
Cost of Medications 
Optum data includes a “standard price” as the cost of a claim, which represents 
the total amount paid by the insurer plus the amount paid by the patient for a medication, 
procedure, medical visit, inpatient stay or other healthcare service. Patient copays, 
deductibles, and dispense fees were subtracted out from the standard price to obtain the 
medication cost incurred by the third-party payer. Patients with schizophrenia may be co-
prescribed multiple types of antipsychotic medication along with their exposure 
medication, therefore, the medication cost calculated in this study is reflective of any 
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antipsychotic use during the follow-up period. LAI administration costs were included in 
the treatment costs as well. Cost was calculated by dividing total cost of medication by 
total follow-up days. Costs for patients with a 60-day medication gap without another 
antipsychotic claim during follow-up were measured until the date of their last exposure-
drug claim plus the remaining days’ supply. Cost was multiplied by 30 days to present a 
monthly figure. 
Gender, age, region, insurance status, health plan type, number of prior 
hospitalizations, and index hospitalization length of stay were utilized as covariates for 
this analysis. 
Statistical Analyses 
A patient level descriptive analysis was conducted to evaluate the differences in 
baseline characteristics between the LAI and oral antipsychotic cohorts (Table 1). Rates 
of adherence and medication switching were measured and compared. The mean cost of 
medication, days of follow-up, age, number of prior hospitalizations, and the index 
hospitalization length of stay was calculated and compared between the two study cohorts 
using chi-squared and t-tests. The mean cost of medication between the two cohorts were 
compared as log-transformed costs and analyzed utilizing a t-test for independent 
samples. 
A decision tree was developed to determine the cost-effectiveness of LAI versus 
oral therapy accounting for patient adherence rates (Figure 3). Branches were constructed 
as the proportion of patients that were adherent or non-adherent per cohort. The 
probability of adherent or non-adherent patients remaining stable in follow-up (no 
rehospitalization or medication switch) was applied. A third-party payer perspective and 
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one-year time-horizon were utilized. The decision tree was modeled and analyzed using 
TreeAge Pro 2019, R1©.34 
Study Outcomes 
The decision analysis defined a combined outcome representing a “stable” patient 
as having no rehospitalization due to relapse or switching of treatment during the follow-
up period. This outcome was evaluated according to level of medication adherence using 
MPR and across treatment cohorts listed in Table 2. 
Establishing which treatment type was more cost-effective was calculated through 
an incremental cost-effectiveness ratio (ICER). The numerator of the ICER value 
represented the difference in mean cost of medication and the denominator represented 
the difference in exposure drug effectiveness (percentage of patients who neither 
switched regimen nor experienced a rehospitalization due to relapse, i.e. stable patients).  
A deterministic sensitivity analysis was conducted using TreeAge Pro 2019, 
R1©.34 A tornado diagram was developed to address uncertainty within the model. The 
analysis illustrates variations in the input parameters that affect the calculated ICER value 
such as increasing the proportion of adherent patients receiving LAIs to 100% and 
decreasing proportion of adherent patients receiving oral SGAs to 0%. All drug cost 









A total of 5,312 patients with schizophrenia were identified during the index 
period. After applying the pre-index, follow-up and age criteria, 631 patients were 
identified; 291 patients were excluded who did not have a pharmacy dispensing for an 
SGA or LAI SGA during the 40-day exposure period following discharge from the index 
hospitalization, 157 patients were excluded who received a LAI SGA prescription before 
their index hospitalization or who were deemed to have extensive inpatient use. An 
additional 25 patients who received oral aripiprazole as an exposure drug or switched to 
LAI after the exposure period, were removed. Only patients with an oral medication for 
which a LAI form was available were included and because no patients in the LAI cohort 
received aripiprazole, these patients were excluded. The final population included 158 
patients (Figure 1). 
Descriptive analysis 
The mean age of the study population upon index hospitalization was 48-years 
(standard deviation, SD +12.0) with similar distribution observed in gender (49.4% 
female). The majority of patients were covered by Medicare (81.7%) and were located in 
the Midwest or South regions (69.0%) of the US. Patients experienced about 4 
hospitalizations (SD +2.7) on average, prior to their index date and had a mean index 
length of stay of about 10 days (SD +8.8) (Table 1). 
A total of 135 (85.4%) patients were classified to the oral antipsychotic cohort 
and 23 (14.6%) patients to the LAI cohort. Age distribution was similar in both cohorts, 
with an average age of 48.5 years (SD +12.4) for patients in the oral antipsychotic cohort 
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and 48.4 years (SD +10.0) for patients in the LAI cohort (p=0.94). Patients in the LAI 
cohort were more likely to be male than those in the oral antipsychotic cohort. 
Distributions of mean index length of stay (9.9 vs. 9.5 days, p=0.82) and mean prior 
hospitalizations (3.2 vs. 3.7 days, p=0.23) were similar between the LAI and oral cohorts, 
respectively. Patients in the oral antipsychotic cohort had about 310 days (SD +127.3) of 
follow-up on average, compared with an average of 299 days (SD +135.3) for the LAI 
cohort (p=0.69). 
Outcomes 
Of the 135 patients receiving oral antipsychotics, 67 (49.6%) were prescribed 
risperidone and 61 were prescribed (45.2%) olanzapine during the exposure period. The 
other 23 patients all received a LAI SGA.  
Compared to patients receiving oral antipsychotics, patients receiving LAIs 
experienced a higher proportion of adherent patients and higher proportion of stable 
patients, although these differences were not statistically significant. Patients receiving 
LAIs had a higher mean monthly cost of medication ($1339.20 vs. $282.90, p<.0001). 
The statistical comparison for costs involved log transformed values as the skewness and 
kurtosis values for non-transformed costs were relatively high (LAI: 3.46, 12.46 ; PO: 
2.11, 4.21, respectively). Skewness and kurtosis for log-transformed values were 
calculated at 2.93 and 9.57 for LAI costs and 0.26 and -0.92 for oral costs, respectively. 
Adherence and cost figures are presented in Table 2 and Table 3. 
The decision tree captured costs for patients according to a level of adherence and 
the combined endpoint of medication switch or rehospitalization, as compared with not 
experiencing either of these outcomes (i.e. remaining stable) during follow-up. The 
 13 
branch probabilities and costs are shown in the decision tree in Figure 3. The mean costs 
for the oral and LAI cohorts after implementing adherence and state probabilities, were 
estimated to be $259.91 and $1322.04, respectively. 
Sensitivity Analysis 
A deterministic sensitivity analysis was conducted to address uncertainty within 
the developed decision tree model. Adherence and cost inputs were modified to illustrate 
changes in the ICER value. Figure 4 addresses multiple variations on the range of the 
base-values in the decision model that would make the ICER value more or less favorable 
for LAIs. The diagram included increased LAI adherence (proportion of adherent patients 
increased to 100%), decreased oral adherence (proportion of adherent patients decreased 
to 0%), and a 50% decrease and increase to all treatment costs. The sensitivity analysis 
suggests that a minor increase in the proportion of adherent patients receiving LAIs, leads 
to a lower ICER value and improved treatment value. 
 
Discussion 
This study applied a retrospective cohort analysis using a real-world sample 
obtained from Optum’s de-identified Clinformatics Data Mart Database 29 to examine 
the cost and outcomes of two different medication classes, oral SGAs and LAI SGAs, in 
patients with schizophrenia. Patients with a history of inpatient hospitalizations were the 
primary focus of this study as LAIs have often been intended for patients that have more 
severe forms of schizophrenia or patients with a history of relapse and non-adherence.35 
Therefore, we required that all patients were required to have at least two inpatient 
hospitalizations for schizophrenia prior to their index hospitalization. Although guidance 
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is limited on this criterion of two or more prior hospitalizations, it was necessary to help 
narrow the cohort to patients who are more likely to be prescribed LAIs and achieve a 
disease severity that was similar between the oral and LAI treatment groups. Despite the 
large population for study provided by the data source, after the application of our 
inclusion criteria only a small number of cases remained for our analysis. This 
necessitated the combining of the study outcomes of rehospitalization and medication 
switch into a composite outcome, and also diminished statistical power when evaluating 
between-group differences. 
The ICER value was calculated through the decision tree to incorporate the 
impact of medication adherence and to assess the incremental cost required for an 
additional outcome of interest associated with the use of LAIs over oral SGAs. According 
to the Institute for Clinical and Economic Review, an ICER ratio often uses quality 
adjusted life years (QALY) as the measure of effectiveness (denominator) to assess 
value.36 However, our study did not aim to measure long-term survival or impact on 
patient quality of life, and thus QALY was not measured. The denominator of the ICER 
ratio in our study was representative of the numerical difference in the proportion of 
stable patients between the LAI and oral treatment groups. Willingness to pay (WTP) 
thresholds are often used when calculating ICER values to determine if a treatment is a 
cost-effective alternative to the comparative treatment. The Institute for Clinical and 
Economic Review recommends US based studies use WTP thresholds of $50,000-
$150,000 per QALY to guide considerations for the value of the alternative treatment 
option.36 However, other similar studies have reported ICER results using QALY as the 
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outcome measure,25,26,40 and we were unable to find any published data describing 
thresholds for willingness to pay for treatment stability in schizophrenia. 
Interpreting ICER values between studies can be difficult due to variation in how 
cost and effectiveness inputs are derived. Previous studies have demonstrated estimated 
ICERs of about $14,500/QALY and $26,800/QALY (to their respective study years) 
when comparing LAIs to oral SGAs.25,26 However, QALY was utilized as an 
effectiveness measure and drug treatment costs were combined with inpatient, outpatient, 
and rehabilitation clinic costs. Therefore, a direct comparison of ICER values may not be 
accurate. While our study did not incorporate non-pharmacological treatment costs, we 
did measure all antipsychotic use to represent an average monthly cost categorized under 
the exposure medication sub-groups. One US-based study analyzed the antipsychotic 
medication costs of LAI risperidone and oral SGAs in a clinical trial in 2009. The cost of 
LAI risperidone including other antipsychotic medications was estimated to be over 
$1900 per quarter for an estimated monthly cost of approximately $650. Oral SGAs 
including other antipsychotic medications was estimated to be $1150 or approximately 
$380 per month.37 Although this study illustrates just under a twofold increase in cost 
when comparing LAI risperidone and oral SGAs, our study suggests that LAI risperidone 
and other LAI SGAs are associated with an even higher cost when compared to oral 
agents. 
Adherence can be measured in a number of ways. As discussed, we utilized MPR 
to assess adherence in our study. Mean adherence was not calculated, instead patients 
were classified into adherent (>0.80) or nonadherent (<0.80) categories based on their 
individual MPR in the follow-up period. While this does not represent the exact 
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adherence rate a patient may experience with a LAI SGA or oral SGA, dichotomizing the 
adherence measure is a common approach in the literature. Moreover, classifying 
adherence in categories allows for the calculated proportions to be analyzed within a 
decision tree. This is a common method when incorporating adherence into a cost-
effectiveness analysis with a decision model, as prior studies suggest.25,26,40 
Switching antipsychotic treatment is common among patients with schizophrenia. 
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, a large 
multi-site, nationwide, trial, assessed the effectiveness of oral antipsychotic medication in 
1,493 patients with chronic schizophrenia.38 It was found that on average, 74% of the 
study population discontinued the study medication within 18-months due to efficacy or 
intolerability. In our study, 29% of patients discontinued their exposure antipsychotic 
medication and started on another non-exposure antipsychotic and about 15% 
discontinued their exposure medication but did not start another antipsychotic medication 
(not classified as switch). While these rates cannot be directly compared to results from 
the CATIE study due to differences in follow up time, study population, and other 
factors, our results nevertheless corroborate that a substantial proportion of patients do 
not persist with the prescribed medication. 
A deterministic sensitivity analysis was conducted to assess uncertainty within the 
decision model (Figure 4). It was determined that any change in the proportion of 
adherent patients has a large impact on the ICER, specifically the proportion of patients 
adherent to LAIs. Due to the small numerical difference in incremental effectiveness at 
base-case inputs, the value becomes highly sensitive to any change in a path probability. 
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To better illustrate the change in the ICER value by LAI adherence, a one-way sensitivity 
analysis of the proportion of adherent patients receiving LAIs was conducted (Figure 5). 
In spite of the established clinical benefits LAIs offer to patients with 
schizophrenia, this class of antipsychotics is still prescribed much less frequently than 
their oral comparators. Only about 15% (n=23) of the study population was prescribed 
LAIs in our study. One recent claims-based study that utilized Truven Health Analytics 
MarketScan Medicaid data from 2010-2013, measured the outcomes of LAIs compared 
to oral antipsychotics in patients with schizophrenia. Patients were required to have a 
recent (6-month) history of non-adherence. Out of about 4,000 patients that met inclusion 
criteria, the researchers identified 340 users of a LAI antipsychotic (about 9%) within 30 
days of their index hospitalization. Of those patients, only 183 patients (about 5%) were 
prescribed a LAI SGA (risperidone or paliperidone).32 Another claims-based study 
assessing the effectiveness of LAIs in comparison to oral agents found that about 15% of 
LAI naïve patients were initiated on any LAI with about 7% initiating a LAI SGA.39 
Future studies are warranted that explore the boundaries around the accessibility and 
prescribing inclinations of LAIs, specifically LAI SGAs. 
Limitations 
This study has multiple limitations that warrant discussion. Due to the 
retrospective and observational nature of this study, it is subject to selection bias. This 
was mitigated through detailed inclusion and exclusion criteria that yielded two similar 
cohorts. Adherence was limited to the information provided with the pharmacy claims 
data and is only representative of the exposure medication. Patients with gaps in their 
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exposure drug claims were assumed to be non-adherent. Data describing medication use 
and treatment during inpatient visits were not available with the data source used. 
The sample size of our study was relatively small, which therefore diminishes 
statistical power when evaluating differences between the two treatment groups. We were 
also unable to identify any patients that received LAIs administered in outpatient clinics. 
HCPCs codes were utilized in addition to NDC codes to account for such patients, 
however, this did not yield additional patients. Despite a small sample size, the rate of 
which patients are prescribed LAIs is accurate and comparable to previous US claims-
based studies.32,39 To detect a statistically significant difference between the effectiveness 
values of both treatment cohorts measured in our study, it is suggested that the population 
size of the LAI and oral cohorts be approximately 2,500 and 14,700 patients, 
respectively. 
Cost of treatment can be difficult to capture when measuring adherence, as 
patients who are nonadherent will have lower costs than those who are not. To attempt to 
control for this issue, patients without an exposure drug claim 60 days after their last 
days’ supply were identified and their costs were measured from the first claim of the 
exposure drug to the last claim of the exposure drug. However, patients with smaller gaps 
between exposure medication fills were not accounted for when measuring cost. Average 
monthly cost is also representative of any antipsychotic use as many patients with 
schizophrenia received multiple antipsychotic medications on a monthly basis. Patients 
prescribed LAIs also typically receive the oral dosage form of the drug along with their 
injectable, which is an added cost that needed to be captured. Costs are presented in their 
respected years of payment, as they were not adjusted for inflation. 
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This study also does not include aripiprazole LAI as it was approved by the US 
Food and Drug Administration in 2013.41 Patients are more likely to be prescribed other 
LAI SGAs that were available before the release of aripiprazole LAI (paliperidone, 
olanzapine, or risperidone) as many patients’ index discharge dates were around the time 
of approval. Patients with an exposure drug claim for oral aripiprazole were removed to 
make the two cohorts more comparable. 
Lastly, this model is limited to a one-year timeframe, however, incorporating a 
longer timeframe is challenging given the disease pathway and a higher rate of patients 
switching their medication is likely to occur.38 This makes it furthermore challenging to 
measure outcomes over a longer time period. However, a one-year follow-up period is 
common in cost-effectiveness studies for evaluating the short-term outcomes of newly 
initiated LAI antipsychotic therapy.25,26,35,40 
Despite these limitations, we believe that this is the first cost-effectiveness 
analysis comparing LAI SGAs to oral SGAs with Optum data. Providing insights into 
both public and commercially insured patients, as a contrast with only publicly insured 











This study offers real-world evidence for the use of LAI SGAs. Although 
statistically not significant, the LAI cohort was associated with numerically lower rates of 
switch or rehospitalization and a higher proportion of adherent patients compared to oral 
SGAs. Although LAIs are associated with a much higher average monthly cost than their 
oral comparators, their intended benefit to prevent medication switch or relapse was 
modeled in our study. However, due to the small sample size and statistically non-
significant results, these findings may not be sufficiently precise. We recommend that our 
findings not be used for policy decisions. Further research is warranted with a larger 
sample size and in terms of cost-benefit, which can illustrate cost-avoidance through the 
cost of rehospitalization due to relapse. With the potential for further expansion of new 
agents in the LAI antipsychotic class, generic drug development, and increased 
awareness of the benefits provided by LAIs, treating a chronic mental illness like 











Table 1. Baseline demographics of patients with schizophrenia (*Cell counts <11) 
       Total (n=158)        PO (n=135)           LAI (n=23) PO vs. LAI 
        n     %        n    % 
           
n     % p Value 
Age at index, years          
18-39 33 20.89 28 20.74 * *   
40-49 39 24.68 31 22.96 * *   
50-59 57 36.08 50 37.04 * *   
60< 29 18.35 26 19.26 * *  
Gender          
Male 80 50.63 67 49.63 * *   
Female 78 49.37 68 50.37 * *  
Region          
Northeast 18 11.39 15 11.11 * *   
Midwest 47 29.75 40 29.63 * *   
South 62 39.24 56 41.48 * *   
West 31 19.62 24 17.78 * *  
Insurance          
Medicare 129 81.65 108 80.00 * *   
Commercial 29 18.35 27 20.00 * *  
Product          
Health Maintenance Org. 76 48.10 66 48.89 * *   
Other 82 51.90 69 51.11 * *  
Prior Hospitalizations          
2 67 42.41 57 42.22 * *   
 3-5 73 46.20 63 46.67 * *   
5< 18 11.39 15 11.11 * *  
Index length of stay, days          
 1-5 56 35.44 52 38.52 * *   
 6-10 50 31.65 45 33.33 * *   
10< 52 32.91 38 28.15 * *  
           
  Total (n=158) PO (n=135) LAI (n=23)   
  Mean Std Dev  Mean Std Dev 
  
Mean  Std Dev   
Age at index, years 48.4 11.96 48.54 12.4 48.35 9.97 0.94 
Prior Hospitalizations 3.63 2.74 3.70 2.90 3.22 1.44 0.23 
Index length of stay, days 9.53 8.75 9.50 9.10 9.91 6.58 0.82 
Follow-up, days 308.57 128.12 310.24 127.32 298.83 135.25 0.69 
Switch 175.57 115.61 184.32 119.54 * *  




Table 2. Results: Adherence, stability, medication switch, and relapse (*Cell counts <11) 
  PO (n=135) LAI (n=23) 
  >0.80 <0.80  >0.80 <0.80 
           n     %   n            %     n 
   
% 
    
n 
       
% 
Total 81 60.00 54 40.00 * * * * 
Stable 53 67.95 25 32.05 * * * * 
Switch 19 50.00 19 50.00 * * * * 
Relapse   *         * * * * * * * 
 
Table 3. Monthly cost of antipsychotic treatment, $ (*Cell counts <11) (^log transformed) 
  PO (n=135) LAI (n=23) PO vs. LAI^ 
  Mean Std Dev Mean Std Dev p Value 
Total 282.90 432.63 1339.20 694.07   
Risperidone 152.10 252.61 902.40 239.06   
Olanzapine 363.90 515.45 *    *   
Paliperidone 930.60 409.65 1466.10 753.56 <.0001 
Stable 315.00 402.88 1296.00 710.30   
Risperidone 160.20 183.22 1180.80 224.10   
Olanzapine 408.90 490.39 *    *   
Paliperidone 1080.00 680.32 1315.80 767.59 <.0001 
Switch 312.00 549.40 1504.20 739.71   
Risperidone 162.90 180.08 616.50 190.51   
Olanzapine 348.00 656.16 * *   
Paliperidone 701.70 392.30 1760.40 569.60 <.0001 
Relapse 65.40 180.08 * *   
Risperidone 42.90 134.22 * *   
Olanzapine 69.00 65.97 * *   
Paliperidone * * * *  














Supplementary Table 1. Currently available LAI atypical antipsychotics 
Proprietary Name Generic Name Release to Market Dosage 
Abilify Maintena Aripiprazole March 2013 300mg/month (deltoid/gluteal) 
400mg/month (deltoid/gluteal) 
Aristada Aripiprazole October 2015 441mg/month (deltoid/gluteal) 
662mg/month (gluteal) 
882mg/month or 6 weeks (gluteal)  
1064mg/2 months (gluteal) 
Zyprexa Relprevv Olanzapine December 2009 105mg/2 weeks (gluteal) 
210mg/2 weeks (gluteal) 
300mg/2 or 4 weeks (gluteal) 
405mg/2 or 4 weeks (gluteal) 





Invega Trinza Paliperidone May 2015 273mg/3 months (deltoid/gluteal) 
410mg/3 months (deltoid/gluteal) 
546mg/3 months (deltoid/gluteal) 
819mg/3 months (deltoid/gluteal) 
Risperdal Consta Risperidone October 2003 12.5mg/2 weeks (deltoid/gluteal) 
25mg/2 weeks (deltoid/gluteal) 
37.5mg/2 weeks (deltoid/gluteal) 
50mg/2 weeks (deltoid/gluteal) 
Perseris Kit Risperidone August 2018 90mg/month (SC abdominal) 
120mg/month (SC abdominal) 
SC: Subcutaneous 


































































8,899 All patients with an inpatient 
schizophrenia diagnosis in 2010-
2015 
3,587 Excluded patients without an 
inpatient diagnosis during index 
period 1/1/12-11/21/14 
5,312 Patients with a schizophrenia 
index-hospitalization between 
1/1/2012 – 11/21/2014 
1,284 Excluded patients without 
enrollment 24 months prior to index 
date 
4,210 Patients with schizophrenia 
who meet age criteria with an 
index hospitalization 
1,326 Excluded patients without 
enrollment 405 days after index 
hospitalization 
2,926 Patients with schizophrenia 
who meet age criteria during index 
period with enrollment for 24 
months prior 
 
1,102 Excluded patients who were 
not within age 18-64 years on index 
hospitalization 
1,600 Continuously enrolled 
patients with schizophrenia in 
index, pre-index, & who matched 
age criteria 
 
631 Continuously enrolled patients 
with schizophrenia in index, pre-
index, & who matched age and 
prior hospitalization criteria 
 
 
969 Excluded patients without at 
least 2 schizophrenia hospitalizations 
during pre-index period 
448 Excluded patients without an 
SGA or LAI prescription within 40 
days of index discharge or with a 
LAI prescription before index and 
with extensive inpatient use on 
index, 60+ days 
183 Continuously enrolled patients 
with schizophrenia in index and pre-
index period. Matched age/prior 
hospitalization criteria, are prescribed 




135 PO SGA in 
exposure period 
23 LAI SGA in 
exposure period 
25 PO SGA 
patients removed 
on aripiprazole 



















• Pre-index: 24 months prior to index date 
• Index date: most recent 295 hospitalization during index period 
• Exposure period: 40-day exposure window for oral SGA or LAI SGA prescription after 
index date discharge 












(Jan 1 2010-Dec 31 2011) 
 
Follow-up period 
(Jan 1 2012-Dec 31 2015) 
Index Period 





12-month follow-up period 
Index Date 
Most recent ICD-9 295* 
hospitalization in  









































LAI Adherent Switch/Rehospitalization Cost 
LAI Adherent Stable Cost 
Cost 
PO Adherent Stable Cost 
Cost 
LAI Non-adherent Switch/Rehospitalization Cost 
LAI Non-adherent Stable Cost 
PO Adherent Switch/Rehospitalization Cost 
PO Non-adherent Stable Cost 
PO Non-adherent Switch/Rehospitalization Cost 
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